Photo taken from Dhruba Deb/LinkedIn
May 19, 2024, 10:55
Dhruba Deb: The 8 SCLC projects Lung Cancer Research Foundation recently funded
Dhruba Deb, at Lung Cancer Research Foundation, shared on LinkedIn:
“As treatment options for SCLC have always been limited, accelerated FDA approval of Tarlatamab-dlle for extensive stage SCLC is a celebration for patients and advocates and an ode to the past and present research.
At Lung Cancer Research Foundation, I’m remembering the 8 SCLC projects we recently funded!
- Uncovering novel vulnerabilities to treat SCLC therapy resistance- Ann Pendergast.
- Using Social Determinants of Health to Predict Adherence of Lung Cancer Screening in Minority High-Risk Smokers- Loretta Erhunmwunsee.
- Pulmonary high-grade neuroendocrine carcinomas as indications for antibody-drug conjugates targeting TROP2 and HER2– Carl Gay.
- Harnessing DLL3 as a CAR T target in small cell lung cancer- Bingnan Zhang.
- A Human Pluripotent Stem Cell-Based Approach to Metastasis of Small Cell Lung Cancer- Huanhuan Chen.
- Deep whole genome sequencing of circulating tumor DNA for studying evolution and therapy resistance in small cell lung cancer- Benjamin B. Morris.
- Targeting MAST1-BCL2 signaling in small cell lung cancer- Lingtao Jin.
- Targeting tumor-immune microenvironment to improve durvalumab efficacy in small celllung cancer- Lingtao Jin.”
Source: Dhruba Deb/LinkedIn